Compared to linear GBAs, macrocyclic GBAs have a much lower risk profile due to their enhanced stability. Linear agents have a higher propensity to release free gadolinium ions, which can lead to toxicity. In contrast, the macrocyclic structure provides a more secure chelation, making them preferable in clinical settings, especially for patients with compromised renal function.
